Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.

@article{Alloo2012PhotodynamicTF,
  title={Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.},
  author={Allireza Alloo and Lilit Garibyan and Nicole R Leboeuf and George Lin and Andrew E. Werchniak and Frank Stephen Hodi and Keith T. Flaherty and Donald P. Lawrence and Jennifer C Y Lin},
  journal={Archives of dermatology},
  year={2012},
  volume={148 3},
  pages={363-6}
}
BACKGROUND The development of keratoacanthomas (KAs) and well-differentiated squamous cell carcinomas (SCCs) is a known adverse effect of novel BRAF inhibitors such as vemurafenib. With multiple such neoplasms often arising after BRAF inhibitor therapy, surgical excision is often impractical. OBSERVATIONS We describe a patient with stage IV melanoma who received the BRAF inhibitor vemurafenib (recently approved by the US Food and Drug Administration) as part of a clinical trial and developed… CONTINUE READING